lyophilization is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-08. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
Several factors accelerate degradation: alkaline pH, elevated temperature, exposure to oxidants, and the presence of residual moisture. Deamidation of asparagine residues and oxidation of methionine are the most commonly reported degradation routes. Because the peptide lacks disulfide bonds, it does not undergo the thiol-related aggregation seen in some other biologics, but physical aggregation can still occur at high concentration. Stability data are product-specific, and extrapolating shelf life between formulations is not reliable.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
== Tethelin (Roberson's patent and trade-mark) == In March 1916, Robertson published a suite of five interconnected articles in the Journal of Biological Chemistry, describing the process through which a material, which he called tethelin (from τεθηλώς, 'growing'), he and his assistant, Louis Adolph Ray (1886-1960), had extracted (in 1915) from the anterior lobes of ox pituitaries acquired from a local slaughterhouse (BR.22), and its positive effects on the growth of his experimental mice (BR.23–BR.26). Robertson claimed that the substance was the pituitary's "growth-controlling principle"; and, according to Robertson's account, on-going research demonstrated that tethelin not only controlled growth, but was very effective in the treatment of ulcers of long standing and slow-healing wounds. Prior to the (March 1916) publication of his discoveries, Robertson had not only been granted the US patent (BR.18) and the UK patent (BR.19) for the "Tethelin" extraction process, but had also begun to use the trade-mark TETHELIN, the rights to which he was subsequently granted in December 1916 (BR.21). Well aware of Jokichi Takamine's earlier struggle to patent adrenalin, and the challenges and time delays Takamine experienced, Robertson simply patented his process, and not his product.
The amended article now defines the participation of the Federal Council and the 16 German states in matters concerning the European Union. Article 29 was again modified and provided an option for the states to "revise the division of their existing territory or parts of their territory by agreement without regard to the provisions of paragraphs (2) through (7)". Article 118a was introduced into the Basic Law and provided the possibility for Berlin and Brandenburg to merge "without regard to the provisions of Article 29, by agreement between the two Länder with the participation of their inhabitants who are entitled to vote". A state treaty between Berlin and Brandenburg was approved in both parliaments with the necessary two-thirds majority, but in a popular referendum of 5 May 1996, about 63% voted against the merger. The German states can conclude treaties with foreign countries in matters within their own sphere of competence and with the consent of the federal government (Article 32 of the Basic Law). Typical treaties relate to cultural relationships and economic affairs. Some states call themselves a "free state" (Freistaat). It is merely a historic synonym for "republic" and was a description used by most German states after the abolition of monarchy after World War I. Today, Freistaat is associated emotionally with a more independent status, especially in Bavaria. However, it has no legal significance. All sixteen states are represented at the federal level in the Bundesrat (Federal Council), where their voting power depends on the size of their population.
Despite Jinnah International Airport serving as the primary international gateway, significant international traffic also flows through Lahore, Islamabad, Peshawar, Quetta, Faisalabad, Sialkot, and Multan airports. The civil aviation industry, deregulated in 1993, operates with a blend of public and private entities while state-owned Pakistan International Airlines (PIA) dominates, carrying 73% of domestic passengers and all domestic freight.
Sources: en.wikipedia.org
=== Baked goods and confectioneries === Cakes are considered to be intermediate moisture foods because of their moisture content (18-28%), and have low enough water activity that preserve the safety and quality. Some examples of baked goods and confectionery that come under this category are fruit cakes, pie fillings, candies, marshmallows, jams, pizza crust. Tutti Fruiti is a candy-like product that can be made from a variety of fruit, most commonly papaya. Raw pieces of unripe papaya are boiled and layered with sucrose until reaching 68 degrees brix. The solution is then air dried until a moisture content of 25.7% is reached.
===== MeSH D08.811.913.050 – acyltransferases (EC 2.3) ===== MeSH D08.811.913.050.080 – acetyl-CoA C-acyltransferase MeSH D08.811.913.050.134 – acetyltransferases MeSH D08.811.913.050.134.029 – acyl-carrier protein s-acetyltransferase MeSH D08.811.913.050.134.060 – acetyl-CoA C-acetyltransferase MeSH D08.811.913.050.134.105 – amino-acid n-acetyltransferase MeSH D08.811.913.050.134.150 – carnitine O-acetyltransferase MeSH D08.811.913.050.134.170 – chloramphenicol o-acetyltransferase MeSH D08.811.913.050.134.180 – choline o-acetyltransferase MeSH D08.811.913.050.134.310 – dihydrolipoyllysine-residue acetyltransferase MeSH D08.811.913.050.134.375 – glucosamine 6-phosphate n-acetyltransferase MeSH D08.811.913.050.134.407 – histone acetyltransferases MeSH D08.811.913.050.134.440 – p300-CBP coactivator family MeSH D08.811.913.050.134.440.249 – creb-binding protein MeSH D08.811.913.050.134.440.600 – e1a-associated p300 protein MeSH D08.811.913.050.134.700 – phosphate acetyltransferase MeSH D08.811.913.050.134.850 – serine O-acetyltransferase MeSH D08.811.913.050.170 – acyl-carrier protein s-malonyltransferase MeSH D08.811.913.050.173 – 1-acylglycerol-3-phosphate O-acyltransferase MeSH D08.811.913.050.175 – 1-acylglycerophosphocholine O-acyltransferase MeSH D08.811.913.050.200 – aminoacyltransferases MeSH D08.811.913.050.200.400 – gamma-glutamylcyclotransferase MeSH D08.811.913.050.200.500 – gamma-glutamyltransferase MeSH D08.811.913.050.200.700 – peptidyl transferases MeSH D08.811.913.050.200.800 – transglutaminases MeSH D08.811.913.050.200.800.300 – factor xiiia MeSH D08.811.913.050.276 – 5-aminolevulinate synthetase MeSH D08.811.913.050.294 – arylalkylamine n-acetyltransferase MeSH D08.811.913.050.313 – arylamine N-acetyltransferase MeSH D08.811.913.050.331 – atp citrate (pro-s)-lyase MeSH D08.811.913.050.350 – carnitine acyltransferases MeSH D08.811.913.050.350.170 – carnitine O-acetyltransferase MeSH D08.811.913.050.350.200 – carnitine o-palmitoyltransferase MeSH D08.811.913.050.368 – citrate (Si)-synthase MeSH D08.811.913.050.387 – diacylglycerol o-acyltransferase MeSH D08.811.913.050.425 – glycerol-3-phosphate O-acyltransferase MeSH D08.811.913.050.600 – homoserine O-succinyltransferase MeSH D08.811.913.050.612 – hydroxymethylglutaryl-CoA synthase MeSH D08.811.913.050.614 – 2-isopropylmalate synthase MeSH D08.811.913.050.618 – malate synthase MeSH D08.811.913.050.622 – 3-oxoacyl-(acyl-carrier-protein) synthase MeSH D08.811.913.050.625 – phosphatidylcholine-sterol O-acyltransferase MeSH D08.811.913.050.646 – retinol O-fatty-acyltransferase MeSH D08.811.913.050.668 – serine C-palmitoyltransferase MeSH D08.811.913.050.712 – sphingosine N-acyltransferase MeSH D08.811.913.050.799 – sterol O-acyltransferase
The Enzyme Function Initiative (EFI) is a large-scale collaborative project aiming to develop and disseminate a robust strategy to determine enzyme function through an integrated sequence–structure-based approach. The project was funded in May 2010 by the National Institute of General Medical Sciences as a Glue Grant which supports the research of complex biological problems that cannot be solved by a single research group. The EFI was largely spurred by the need to develop methods to identify the functions of the enormous number proteins discovered through genomic sequencing projects.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
Dry lyophilized powder tolerates short ambient exposure during handling and shipping. Long-term room-temperature storage is not recommended because moisture uptake and slow degradation can occur over months. Storage at minus twenty degrees Celsius is the common practice for extended periods.